BAX and adult T-cell leukemia/lymphoma: By directly exploiting the apoptotic vulnerability created by enhanced BAX expression, Navitoclax represents a powerful targeted approach to counteract HTLV-1-mediated oncogenesis and overcome the apoptotic resistance that characterizes ATLL [59].